ArticlePloS one2017

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.

Katharine Victoria Jensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.